Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders. The company is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.

MedImmune Oncology, Inc. engages in the clinical development of medicines to treat cancer. The company is headquartered in Gaithersburg, MD.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Clinigen Group Plc engages in the provision of pharmaceutical products and services. It operates through the following segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires rights to niche hospital-only and critical care products and also provides access to licensed and branded generic. The Unlicensed Medicines segment supplies unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Services offers comparator medicines and services to clinical trials and IITs. The company was founded by Andrew Leaver in June 2010 and is headquartered in Burton-on-Trent, the United Kingdom.

Cellatoz Therapeutics with the goal of resolving the unmet medical needs of incurable diseases. Korea's top R & D specialists gather to discover differentiated therapeutic cell and platform technologies, and promote the commercialization of cell therapy products based on the company's intermediary research and product development capabilities.Cellatoz Therapeutics are the first in the world to acquire musculoskeletal stem cell (MSSC) induction technology capable of final differentiation from embryonic stem cells and inducible pluripotent stem cells (iPSC) into mesodermal tissue cells. By modulating the cell differentiation signals of the cells, we are developing a therapeutic agent for musculoskeletal-related diseases (eg compound fracture, arthritic cartilage damage, etc.) that can regenerate and repair the tissue of the musculoskeletal injured area.

Adhaere Pharmaceuticals is a provider and developer of novel therapeutics in Skokie.

Faron Pharmaceuticals Oy operates as a clinical stage biopharmaceutical company. It develops novel treatments for medical conditions with significant unmet needs caused by dysfunction of immune system. The firm currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Its Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. The company was founded by Juho Markku Jalkanen, Sirpa Tuulikki Jalkanen, Matti Esa Manner, Juha Peltola, Marko Salmi, Katriina Peltola and Maija-Leena Hollmen in 2003 and is headquartered in Turku, Finland.

U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA.

GB006, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, CA.

StemCyte, Inc. operates as an umbilical cord blood stem cell transplantation and therapeutic products company. It provides cord blood products to transplant centers for life-threatening diseases. The company's products are used to treat patients suffering from various blood cancers, and immune and genetic disorders. StemCyte, Inc. was founded in 1997 and is headquartered in Covina, California. It operates umbilical cord blood storage facilities in California and Taiwan. The company has locations in the United States, India, and Taiwan.

Elixirgen Therapeutics is a biotechnology company focused on curing humanity’s ailments through stem cell biology. The company concentrates on regenerative and rejuvenative medicine and deals with research in both basic science and in the application of the technologies it discovers and refines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics’ scientists to conduct research at state-of-the-art facilities. Elixirgen Therapeutics inherits all the therapy-related assets, including intellectual property, from its parent company, Elixirgen, LLC, which has been in active operation since the beginning of 2012.

Zhuhai Bohua Biological Engineering Co., Ltd., established on 2014-06-19, The business scope includes the business scope recorded in the articles of association:Research and development of biological and biochemical products,Research and experimental development in the fields of medicine and biotechnology;Production and salesΙ,II,Class III medical device,Biological product;Clinical Medical Laboratory Services;Consultation and promotion of medical testing and medical technology;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Chungbuk National University Industry-Academic Cooperation Fou is a private company headquartered in the South Korea that operates as university.